translation agency

NLM AIDSLINE
Protease inhibitors shine in triple combinations. Clearinghouse, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5714.

September 30, 1996
AIDS Alert. 1996 Mar;11(3):31-2. Unique Identifier : AIDSLINE

Ritonavir, a protease inhibitor, demonstrated strong antiviral activity when combined with AZT and ddC at dosage levels of 1200, 600 and 2.25 mg respectively. Six-month therapy resulted in a median CD4 count increase that was nearly double from baseline, and significant viral load reductions that were sustained throughout the study. Ritonavir was generally well tolerated. A study using AZT and 3TC with an experimental protease inhibitor, indinavir, also greatly reduced viral loads. The effects lasted throughout the six-month treatment period. A specific HIV protease gene that contributes to the emergence of resistance during treatment with ritonavir has also been identified.

Acquired Immunodeficiency Syndrome/*DRUG THERAPY Antiviral Agents/ADMINISTRATION & DOSAGE/*THERAPEUTIC USE CD4 Lymphocyte Count Dose-Response Relationship, Drug Drug Therapy, Combination HIV Protease Inhibitors/ADMINISTRATION & DOSAGE/*THERAPEUTIC USE Human Pyridines/ADMINISTRATION & DOSAGE/THERAPEUTIC USE Thiazoles/ADMINISTRATION & DOSAGE/THERAPEUTIC USE Valine/ADMINISTRATION & DOSAGE/THERAPEUTIC USE Zalcitabine/ANALOGS & DERIVATIVES/ADMINISTRATION & DOSAGE/ THERAPEUTIC USE Zidovudine/ADMINISTRATION & DOSAGE/THERAPEUTIC USE NEWSLETTER ARTICLE

www.aegis.org